Lucey found that suvorexant, a different dual orexin receptor antagonist, reduced p-tau181 in CSF of healthy volunteers, aged 45-65 (Lucey et al., 2023). “Since suvorexant did not increase sleep ...

Orexin antagonists like Idorsia’s Quviviq (daridorexant), Eisai’s Dayvigo (lemborexant) and MSD’s Belsomra (suvorexant) are already approved for insomnia itself, by J&J believes that ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai. The ...

Background People with dementia frequently experience sleep disturbances. These can include reduced sleep at night, frequent wakening, wandering at night, and sleeping excessively during the day.

Non-pharmacological approaches are preferred for promoting sleep in the ICU; however, limited but growing evidence supports the use of pharmacological agents.

The two-component crystals formed from pyridine or 4-dimethylaminopyridine with maleic, fumaric, phthalic, isophthalic, or terephthalic acids were characterized by X-ray diffraction. The two-component ...